Macquarie Stem Cells has provided this information to educate the public based on peer reviewed, published scientific and medical documents. We don’t aim to encourage consumers to seek out such treatments prior to an assessment by a health professional to determine your suitability for treatment. This is obtained from NCBI Pubmed Literature. There are no financial sponsors for this article.
Published in the International archives of Medicine Journal in 2012, the clinical use of systemically administered biological treatments has reported in two pilot studies. The first was a description of 3 patients suffering from multiple sclerosis who received an intravenous treatment. All 3 patients reported significant improvement neurologically, and demonstrated an excellent safety profile. Additionally, a patient case report described remission of RA subsequent to administration of a biological intervention.
Let’s start by taking a closer look at the biological treatments and their abilities,
(Rohban and Pieber, 2017) (Fu et al., 2017) (Lauvrud et al., 2016) (Nguyen et al., 2016) (Chen et al., 2016) (Zachar, Bačenková and Rosocha, 2016)
The component we are going to focus on here is the stimulation of Treg activity.
Numerous autoimmune conditions enter remission as a result of increased Treg number and/or activity, whereas relapse is associated with reduction in number and/or activity. Specifically, this has been demonstrated in multiple sclerosis, rheumatoid arthritis and lupus. Given the importance of Treg cells in the control of autoimmunity, it would be useful to possess sources of Treg cells that are easily accessible and can be reintroduced into the patient for immune modulation. (Rodriguez P., et al. 2012)
It is known that the signalling systems known as cytokines leptin and TNF-alpha reduce Treg proliferation and activity. The effects of transferring these signalling systems from a local area through out the body via intravenous infusion has shown to result in enhanced Treg activity for the whole body. (Rodriguez P., et al. 2012)
Given that biological processes including Treg activity are considered to be tolerance-promoting, it may be feasible to consider that the body may enter a tolerance induction stage after the treatment. Rodriguez and Riordan previously reported remission in a patient with rheumatoid arthritis who was treated using biological interventions. Additionally, Riordan’s group and others have reported that increased Treg immune activity is associated with disease remission. (Rodriguez P., et al. 2012)
Ref:Paz Rodriguez, J., Murphy, M., Hong, S., Madrigal, M., March, K., Minev, B., Harman, R., Chen, C., Timmons, R., Marleau, A. and Riordan, N. (2012). Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety. International Archives of Medicine, 5(1), p.5.
Tags: Macquarie Stem Cells, Dr. Bright, Osteoarthritis Treatment, Dr. Ralph Bright, Biological Therapy, Using your own Biology, Rheumatoid arthritis Treatment, Arthritis
Remember, any surgical or invasive procedure carries risks. Before proceeding, you should seek a second opinion from an appropriately qualified health practitioner.